Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models
Open Access
- 14 September 2010
- journal article
- viral hepatitis
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 53 (1), 32-41
- https://doi.org/10.1002/hep.23985
Abstract
The combination of pegylated interferon (PEG‐IFN) and ribavirin is the standard treatment for chronic hepatitis C. Our recent clinical study suggests that ribavirin augments the induction of interferon‐stimulated genes (ISGs) in patients treated for hepatitis C virus (HCV) infection. In order to further characterize the mechanisms of action of ribavirin, we examined the effect of ribavirin treatment on ISG induction in cell culture. In addition, the effect of ribavirin on infectious HCV cell culture systems was studied. Similar to interferon (IFN)‐α, ribavirin potently inhibits JFH‐1 infection of Huh7.5.1 cells in a dose‐dependent manner, which spans the physiological concentration of ribavirin in vivo . Microarray analysis and subsequent quantitative polymerase chain reaction assays demonstrated that ribavirin treatment resulted in the induction of a distinct set of ISGs. These ISGs, including IFN regulatory factors 7 and 9, are known to play an important role in anti‐HCV responses. When ribavirin is used in conjunction with IFN‐α, induction of specific ISGs is synergistic when compared with either drug applied separately. Direct up‐regulation of these antiviral genes by ribavirin is mediated by a novel mechanism different from those associated with IFN signaling and intracellular double‐stranded RNA sensing pathways such as RIG‐I and MDA5. RNA interference studies excluded the activation of the Toll‐like receptor and nuclear factor κB pathways in the action of ribavirin. Conclusion: Our study suggests that ribavirin, acting by way of a novel innate mechanism, potentiates the anti‐HCV effect of IFN. Understanding the mechanism of action of ribavirin would be valuable in identifying novel antivirals (HEPATOLOGY 2011.)This publication has 62 references indexed in Scilit:
- Toll-like receptors: From the discovery of NFκB to new insights into transcriptional regulations in innate immunityBiochemical Pharmacology, 2006
- Ribavirin Monotherapy for Chronic Hepatitis C Infection: A Cochrane Hepato-Biliary Group Systematic Review and Meta-Analysis of Randomized TrialsThe American Journal of Gastroenterology, 2006
- Treating HCV with ribavirin analogues and ribavirin-like moleculesJournal of Antimicrobial Chemotherapy, 2005
- IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon inductionNature Immunology, 2005
- Mechanism of action of interferon and ribavirin in treatment of hepatitis CNature, 2005
- Evasion of intracellular host defence by hepatitis C virusNature, 2005
- Production of infectious hepatitis C virus in tissue culture from a cloned viral genomeNature Medicine, 2005
- Hepatic Gene Expression Discriminates Responders and Nonresponders in Treatment of Chronic Hepatitis C Viral InfectionGastroenterology, 2005
- IRF-7 is the master regulator of type-I interferon-dependent immune responsesNature, 2005
- Isolation and Culture of Hepatic Stellate CellsPublished by Springer Science and Business Media LLC ,2005